Paul M. Loadman

5.3k citations

152 papers · 4.0k indexed · 1 hit paper · h-index 37

Impact in

Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
Toxicology top 1%

Papers in

Toxicology 12
- Bioactive Compounds and Antitumor Agents 12
Cancer Research 39
- Cancer, Hypoxia, and Metabolism 22

Co-authors: Roger M. Phillips Mark A. Hull Robert A. Falconer M C Bibby Steven D. Shnyder J A Double Laurence H. Patterson Jason H. Gill
Journals: Cancer Research (10 papers)Journal of Clinical Oncology (8 papers)British Journal of Cancer (8 papers)Cancer Chemotherapy and Pharmacology (6 papers)European Journal of Cancer (5 papers)
Partner nations: United Kingdom United States Italy

In The Last Decade

Paul M. Loadman

150 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota 2017 · 379 citations

Peers

Countries citing papers authored by Paul M. Loadman

Since Specialization

Citations

This map shows the geographic impact of Paul M. Loadman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul M. Loadman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul M. Loadman more than expected).

Fields of papers citing papers by Paul M. Loadman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul M. Loadman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul M. Loadman. The network helps show where Paul M. Loadman may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul M. Loadman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul M. Loadman Line = papers co-authored together Paul M. Loadman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sidechain structure–activity relationships of cyclobutane-based small molecule αvβ3 antagonists RSC Medicinal Chemistry ·Suzanne Gutwirth, G Elufidodo, Andrew H. Gordon, B. E. Dietzell, Zun-Yuan Zeng, Chevy Kusumah Wardhana, Patricia A. Cooper, Fatma A. Abd Rabou, Paul M. Loadman, Mark W. Sutherland, Steven D. Shnyder, Helen M. Sheldrake	2024	0
2	Maleimide–Thiol Linkages Alter the Biodistribution of SN38 Therapeutic Microbubbles Compared to Biotin–Avidin While Preserving Parity in Tumoral Drug Delivery Pharmaceutics ·Nicola Ingram, Radwa H. Abou‐Saleh, O. M. Dmitriiev, Paul M. Loadman, Richard J. Bushby, Stephen D. Evans, P. Louise Coletta	2024	0
3	The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E₂ synthesis and platelet activation in participants of the seAFOod polyp prevention trial International Journal of Cancer ·I Wachtl, Máté Jenő Kiss, Leonardo Sacco, O. M. Dmitriiev, Amy Downing, Elizabeth A. Williams, Colin Rees, Louise Brown, Paul M. Loadman, Mark A. Hull	2023	3
4	Polymorphisms in Cyclooxygenase , Lipoxygenase , and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial Cancer Prevention Research ·John R. Davies, Alexandra R. Groves, Máté Jenő Kiss, Mark Harland, Rasha N.M. Saleh, O. M. Dmitriiev, Colin Rees, Louise Brown, Paul M. Loadman, Amy Downing, Anne Marie Minihane, Elizabeth A. Williams, Mark A. Hull	2023	6
5	Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues iScience ·P. Auteur de lettres Dorveaux, Sebastian P. Galuska, Paul M. Loadman, Simon E. Ward, Robert A. Falconer, Sherif F. El‐Khamisy	2023	4
6	An assay for quantitative analysis of polysialic acid expression in cancer cells Carbohydrate Polymers ·Xiaoxiao Guo, Clare F. Gleeson, Anjana Patel, Goreti Ribeiro Morais, Steven D. Shnyder, Paul M. Loadman, Laurence H. Patterson, Robert A. Falconer	2021	5
7	Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds Bioorganic & Medicinal Chemistry ·Qianhong Ma, Kersti Karu, Min-Li Hung, Goreti Ribeiro Morais, Helen M. Sheldrake, Steven D. Shnyder, P. Auteur de lettres Dorveaux, Paul M. Loadman, Chevy Kusumah Wardhana, Klaus Pors, Mark Searcey	2021	3
8	Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer Cancer Chemotherapy and Pharmacology ·Roger M. Phillips, Paul M. Loadman, 敏夫筑紫	2019	4
9	Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT SHILAP Revista de lepidopterología ·Mark A. Hull, Kirsty Sprange, Trish Hepburn, Wei Tan, Aisha Shafayat, Colin Rees, Gayle Clifford, Richard F. Logan, Paul M. Loadman, Elizabeth A. Williams, Diane Whitham, Alan Montgomery	2019	13
10	Newcastle University ePrints (Newcastle Univesity) ·Mark A. Hull, Wei Tan, Aisha Shafayat, Colin Rees, Gayle Clifford, Richard F. Logan, Paul M. Loadman, Elizabeth A. Williams, Diane Whitham, (unknown), (unknown), (unknown), (unknown)	2018	79
11	A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota Gut ·Henry Watson, Suparna Mitra, Fiona Croden, Morag Taylor, Henry M. Wood, Sarah Perry, Jade Spencer, Philip Quirke, Giles J. Toogood, Clare Lawton, Louise Dye, Paul M. Loadman, Mark A. Hull Hit paper breakdown →	2017	379
12	Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid Gut ·Andrew J. Cockbain, Milène Volpato, O. M. Dmitriiev, Alessandra Munarini, Chiara Di Fazio, Andrea Belluzzi, Paul M. Loadman, Giles J. Toogood, Mark A. Hull	2014	89
13	Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins Clinical Cancer Research ·Nidhal Mustafa, Klaus Pors, Paul M. Loadman, Steven D. Shnyder, Inger Johansson, Grace O. Daniel, Helen M. Sheldrake, Souren Mkrtchian, Laurence H. Patterson, Magnus Ingelman‐Sundberg	2013	46
14	PWE-163 Chemr23 and BLT1 Receptor Expression in Colorectal Cancer Gut ·DM Baguley, Milène Volpato, Paul M. Loadman, Anna Nicolaou, Kelly McCoy	2013	1
15	Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Molecular Cancer Therapeutics ·Mark Sutherland, Jason H. Gill, Paul M. Loadman, Jonathan P. Laye, Helen M. Sheldrake, Nicola A. Illingworth, Grace O. Daniel, Patricia A. Cooper, Mark Searcey, Klaus Pors, Steven D. Shnyder, Laurence H. Patterson	2012	36
16	Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases Cancer Research ·Jennifer M. Atkinson, Robert A. Falconer, Dylan R. Edwards, Caroline J. Pennington, Catherine S. Siller, Steven D. Shnyder, Michael C. Bibby, Laurence H. Patterson, Paul M. Loadman, Jason H. Gill	2010	48
17	Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study Clinical Cancer Research ·Mark R. Albertella, Paul M. Loadman, Philip H. Jones, Roger M. Phillips, R. Rampling, N.G. Burnet, H. Peng, Alan Anthoney, Egils Vjaters, Chris R. Dunk, Peter A. Harris, Alvin Wong, Alshad S. Lalani, Chris Twelves	2008	98
18	Phase I/II clinical evaluation of intravesical EOquin (EO9) against superficial bladder cancer Cancer Research ·Roger M. Phillips, Paul M. Loadman, Fábio de Araújo Leite, Mohammed Z.A.A. AL-Dulaiei, Victor Palit, 淑敏潘, Anđela Papić, Luigi Lenaz, Shanta Chawla, Diego Fernández Gómez, Rajiv Puri	2005	2
19	Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Bradford Scholars (University of Bradford) ·Paul Gibson, Jason H. Gill, S. Iannielo, Jill M. Seargent, Riccardo Mercati, P A Batman, John Griffith, แผนกวิชาประถมศึกษา คณะครุศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย, John A. Double, Michael C. Bibby, Paul M. Loadman	2003	80
20	Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein Expert Opinion on Therapeutic Patents ·D. Alwyn Dart, Hsuan-Tsung Chiu, Paul M. Loadman, Steven M. Picksley	2001	4

About Paul M. Loadman

Paul M. Loadman is a scholar working on Toxicology, Cancer Research, Oncology, Pharmacology and Biochemistry, having authored 152 papers that have together received 4.0k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (33 papers), Cancer, Hypoxia, and Metabolism (22 papers), Peptidase Inhibition and Analysis (17 papers), Cancer Treatment and Pharmacology (17 papers), Pharmacogenetics and Drug Metabolism (14 papers), Bioactive Compounds and Antitumor Agents (12 papers), Fatty Acid Research and Health (11 papers) and Lung Cancer Research Studies (11 papers). The work is most often cited by research in Cancer Research (865 citations), Toxicology (196 citations), Oncology (1.1k citations), Pharmacology (268 citations) and Molecular Biology (2.1k citations). Paul M. Loadman has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Roger M. Phillips, Mark A. Hull, Robert A. Falconer, M C Bibby, Steven D. Shnyder, J A Double, Laurence H. Patterson, Jason H. Gill, Giles J. Toogood and David J. Swaine. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, British Journal of Cancer, Cancer Chemotherapy and Pharmacology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact